OxyFile #623
AU - Steinhart H
AU - Schulz S
AU - Mutters R
TI - Evaluation of ozonated oxygen in an experimental animal
model of osteomyelitis as a further treatment option for
skull-base osteomyelitis.
AB - The standard treatment of chromic skull-base osteomyelitis
is antibiotics and surgical removal of sequestrums. Hyperbaric
oxygen therapy has been found to be a useful method for
managing refractory cases of chronic osteomyelitis. Since
a minimal blood supply is needed for hyperbaric oxygen
therapy, chronic osteomyelitis can produce necrotic infected
areas that are not nutrified and therefore not assessable
for hyperbaric oxygen therapy. Ozone is known to be an
oxidizing medium with a strong bactericidal effect. We
investigated the influence of locally applied ozonated
oxygen on the development of chronic osteomyelitis in an
experimental animal model using the femur of the rabbit.
The proximal sides of the femurs of 40 rabbits were prepared
and a needle inserted into the intramedullary cavity. Osteomyelitis
was induced with an infusion of Staphylococcus aureus and
sodium morrhuate into the bone. The needle was left in
a intramedular location. After a 4-week delay animals were
randomly separated into treatment and control groups. The
infected femur of treated animals was flushed three times
a day with 20 ml of ozonated oxygen at an ozone concentration
of 107 micrograms/ml O2 over periods of 2 or 4 weeks. Clinical,
radiographic and microbiological findings were documented.
Chronic osteomyelitis occurred in all animals. Ten rabbits
were excluded from further study during the investigation
because of excessive weight loss (> 15% of the original
weight). Bacterial cultures showed no significant reduction
of S. aureus concentrations in the ozone-treated group,
although comparison of radiographic results revealed less
serious osteomyelitis-related bone damage in these animals
(P < 0.01). These findings indicate that refractory osteomyelitis
in the head and neck may benefit from locally applied "
flush" therapy with ozonated oxygen in addition to treatment
with antibiotics, surgery and hyperbaric oxygen.
SO - Eur Arch Otorhinolaryngol 1999; 256(3):153-7
DP - 1999
TA - Eur Arch Otorhinolaryngol
PG - 153-7
VI - 256
UI - 99250745